Robot-assisted sutureless partial nephrectomy for the treatment of fifteen bilateral renal masses in a patient with Von Hippel-Lindau syndrome: a case report from a high-volume robotic center.


Journal

CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244

Informations de publication

Date de publication:
08 2023
Historique:
received: 23 09 2022
accepted: 13 12 2022
medline: 2 8 2023
pubmed: 8 1 2023
entrez: 7 1 2023
Statut: ppublish

Résumé

Renal cell carcinoma is among major causes of death in patients with Von Hippel-Lindau (VHL) syndrome, and it usually presents with multiple and bilateral lesions that may require multiple renal surgeries. This, in turn, may compromise renal function, resulting in end-stage renal disease. To minimize renal function impairment in these patients, great importance is given to the preservation of functional parenchyma with the use of nephron-sparing techniques. Furthermore, new techniques such as off-clamp surgery, selective suturing or sutureless techniques may improve long-term functional outcomes. We described the case of a 27-year-old male patient with a family history of VHL disease affected by multiple, bilateral renal masses. He received bilateral, metachronous robot-assisted partial nephrectomies (RAPN) for a total of 15 renal lesions. No intra- or post-operative complications occurred, and the patient was discharged on the second postoperative day after both procedures. Serum creatinine after the second RAPN was 0.99 mg/dl (baseline value was 1.11 mg/dl). In patients with VHL syndrome and multiple renal lesions, robot-assisted partial nephrectomy, especially with the use of clampless and sutureless techniques, helps minimizing renal function impairment and should be performed when anatomically and technically feasible.

Identifiants

pubmed: 36611089
doi: 10.1007/s13730-022-00770-7
pii: 10.1007/s13730-022-00770-7
pmc: PMC10393926
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

335-340

Informations de copyright

© 2023. The Author(s) under exclusive licence to The Japan Society of Nephrology.

Références

BJU Int. 2022 Nov;130(5):671-675
pubmed: 35689414
Eur J Surg Oncol. 2019 Jul;45(7):1232-1237
pubmed: 30553632
BJU Int. 2014 Nov;114(5):741-7
pubmed: 24690155
Eur Urol. 2011 Jan;59(1):128-34
pubmed: 20971550
Int J Urol. 2019 Oct;26(10):985-991
pubmed: 31342589
J Urol. 2013 Apr;189(4):1229-35
pubmed: 23085300
Eur J Surg Oncol. 2016 Nov;42(11):1729-1735
pubmed: 27106494
J Urol. 2008 Feb;179(2):468-71; discussion 472-3
pubmed: 18076931
Eur Urol. 2019 Sep;76(3):398-403
pubmed: 31080127
Eur Urol Focus. 2022 Mar;8(2):506-513
pubmed: 33775611
J Urol. 2009 Jan;181(1):55-61; discussion 61-2
pubmed: 19012918
Urol Oncol. 2013 Aug;31(6):924-9
pubmed: 21906969
Eur Urol Focus. 2016 Dec 15;2(6):589-600
pubmed: 28723490
Eur Urol. 2008 Apr;53(4):803-9
pubmed: 18036730
Eur Urol. 2022 Feb;81(2):134-137
pubmed: 34920897
Eur J Hum Genet. 2011 Jun;19(6):617-23
pubmed: 21386872
Eur Urol. 2010 Dec;58(6):900-5
pubmed: 21414862
Eur Urol Focus. 2019 Jul;5(4):600-603
pubmed: 28869203
Ann Surg Oncol. 2011 Apr;18(4):1151-7
pubmed: 21136181
J Endocrinol Invest. 2018 Jan;41(1):21-31
pubmed: 28589383
J Med Genet. 1991 Jul;28(7):443-7
pubmed: 1895313
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Eur Urol. 2012 Dec;62(6):1097-117
pubmed: 22841673
Ann Transl Med. 2020 Feb;8(4):134
pubmed: 32175427
J Urol. 2009 Oct;182(4):1271-9
pubmed: 19683266
Eur Urol. 2014 Oct;66(4):713-9
pubmed: 24486306
Int J Urol. 2018 Sep;25(9):826-831
pubmed: 30132976
BJU Int. 2021 Dec;128 Suppl 3:30-35
pubmed: 34448346
Am J Case Rep. 2017 Nov 17;18:1220-1224
pubmed: 29146893
Ann Surg Oncol. 2016 Dec;23(13):4277-4283
pubmed: 27411552
Nat Rev Clin Oncol. 2016 Sep;13(9):537-49
pubmed: 27030075
Eur Urol. 2022 Aug;82(2):233-237
pubmed: 35568597
Eur Urol Oncol. 2021 Aug;4(4):645-650
pubmed: 32646849
Eur Urol. 2010 Sep;58(3):340-5
pubmed: 20825756
Eur Urol Focus. 2021 Mar;7(2):390-396
pubmed: 31727523
J Endourol. 2022 Mar;36(3):317-326
pubmed: 34579555

Auteurs

Maria Peraire Lores (M)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium. mperairelores@gmail.com.
ORSI Academy, Ghent, Belgium. mperairelores@gmail.com.

Jesús Domínguez (J)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Carlo A Bravi (CA)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.
Division of Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.

Angelo Mottaran (A)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.
Division of Urology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.

Luca Sarchi (L)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Marco Paciotti (M)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.
Department of Urology, Humanitas Research Hospital, IRCCS, Rozzano, Milan, Italy.

Adele Piro (A)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.
Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

Luigi Nocera (L)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.
Division of Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.

Eleonora Balestrazzi (E)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.
Division of Urology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.

Rui Farinha (R)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Kim Pauwaert (K)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.

Manoe Van Herwaarden (M)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.

Marie-Hélène Vinckier (MH)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.

Pieter De Backer (P)

ORSI Academy, Ghent, Belgium.

Ruben De Groote (R)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Frederiek D'Hondt (F)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Geert De Naeyer (G)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Alexandre Mottrie (A)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH